Role of PACAP in Nehprotic Syndrome

Universitaire Ziekenhuizen KU Leuven

Status: Completed

Conditions: Nephrotic Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT01411982

S52866

Details and patient eligibility

About

This study will identify the role of PACAP (pituitary adenylate cyclase-activating polypeptide) deficiency in patients with nephrotic syndrome. PACAP is a neuropeptide that has a putative role as an inhibitor of megakaryopoiesis and platelet function. Patients with nephrotic syndrome show decreased PACAP plasma levels, due to urinary loss. We hypothesize that in severe nephrotic syndrome, plasma deficiency of PACAP enhances megakaryopoiesis and causes blood platelet activation, which contribute to the increased rate of thromboembolic disease in these patients.

To test our hypothesis, the role of PACAP deficiency on pro-thrombotic state in patients with nephrotic syndrome will be studied using patient blood and urine samples.

Enrollment: 29 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• New patient with nephrotic syndrome of patient during relapse of nephrotic syndrome
• Under 16 years old
• Treatment for nephrotic syndrome not yet started by first sample collection

Exclusion criteria

• None